Moreover, inhibiting KRas/calmodulin interaction by stimulating PKC-mediated Ser181 phosphorylation of KRas, using the atypical PKC activator prostatin, suppressed tumourigenesis in KRas mutant pancreatic cancer cells as a result of increased CaMKII activity [167]. The gene discussed is PRRT2; the disease is familial pancreatic carcinoma.